Background Bexarotene (Targretin^®) is a synthetic retinoid which is licensed for the treatment of advanced refractory cutaneous T-cell lymphoma (CTCL).

Objectives To summarize our experience with bexarotene for patients with CTCL with the aim of assessing efficacy and safety.

Methods A retrospective study of 66 patients (44 male, 22 female) with mycosis fungoides (40 patients) or Sézary syndrome (26 patients) who were commenced on bexarotene prior to August 2007 was carried out. Nineteen patients had early-stage (IB–IIA) refractory mycosis fungoides and 47 patients had advanced-stage CTCL (IIB–IVB).

Results Fifty-two out of 66 (79%) patients completed over 1 month of therapy with an intention-to-treat response rate of 44% (29/66). Of the patients, six (9%) had a complete response, 23 (35%) had a partial response, 15 (23%) had stable disease and eight (12%) had progressive disease. Median time to maximal response was 3 months (1–9 months). Median response duration was 8 months (1 to > 48 months). Median time to progression was 9 months (3–44 months). Fourteen patients (21%) did not complete a month of bexarotene therapy. Adverse effects of the whole group included central hypothyroidism in 100% (all grade II and managed with thyroid replacement) and hyperlipidaemia in 100% (all managed with lipid-lowering therapy ± dose reduction). Responses were seen in all stages and were higher in advanced stages: 26% (five of 19) with early-stage and 51% (24/47) of advanced-stage disease. Responses were seen in skin, blood and lymph nodes. Twenty-eight out of 66 patients were treated with bexarotene monotherapy and the remainder were on one or more additional anti-CTCL therapies.

Conclusions Our data demonstrate that bexarotene is well tolerated in most patients and responses are seen in almost half of patients with all disease stages. However partial responses were not graded and would include any improvement seen in the skin, blood and lymph node.

References

1 Whittaker SJ, MacKie RM. Cutaneous lymphomas and lymphocytic infiltrates. In: Rook’s Textbook of Dermatology ( T Burns, S Breathnach, N Cox, C Griffiths, eds), 7th edn, Oxford: Blackwell Science Ltd, 2004; 54.1.
Web of Science® Google Scholar
2 Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002. Arch Dermatol 2007; 143: 854–9.
10.1001/archderm.143.7.854
PubMed Web of Science® Google Scholar
3 Kim YH, Liu HL, Mraz-Gernhard S et al. Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome. Arch Dermatol 2003; 139: 857–66.
10.1001/archderm.139.7.857
PubMed Web of Science® Google Scholar
4 Willemze R, Jaffe ES, Burg G et al. WHO–EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768–85.
10.1182/blood-2004-09-3502
CAS PubMed Web of Science® Google Scholar
5 Trautinger F, Knobler R, Willemze R et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006; 42: 1014–30.
10.1016/j.ejca.2006.01.025
PubMed Web of Science® Google Scholar
6 Zackheim HS. Cutaneous T cell lymphoma: update of treatment. Dermatology 1999; 199: 102–5.
10.1159/000018214
CAS PubMed Web of Science® Google Scholar
7 Boehm MF, Zhang L, Badea BA et al. Synthesis and structure–activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 1994; 37: 2930–41.
10.1021/jm00044a014
CAS PubMed Web of Science® Google Scholar
8 Duvic M, Martin AG, Kim Y et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581–93.
CAS PubMed Web of Science® Google Scholar
9 Zhang C, Hazarika P, Ni X et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002; 8: 1234–40.
CAS PubMed Web of Science® Google Scholar
10 Budgin JB, Richardson SK, Newton SB et al. Biological effects of bexarotene in cutaneous T-cell lymphoma. Arch Dermatol 2005; 141: 315–21.
10.1001/archderm.141.3.315
CAS PubMed Web of Science® Google Scholar
11 Talpur R, Ward S, Apisarnthanarax N et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002; 47: 672–84.
10.1067/mjd.2002.124607
PubMed Web of Science® Google Scholar
12 Singh F, Lebwohl MG. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. J Am Acad Dermatol 2004; 51: 570–3.
10.1016/j.jaad.2003.05.010
PubMed Web of Science® Google Scholar
13 Assaf C, Bagot M, Dummer R. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 2006; 155: 261–6.
10.1111/j.1365-2133.2006.07329.x
CAS PubMed Web of Science® Google Scholar
14 Bunn PA Jr, Lambert SI. Report of the Committee of staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 1979; 63: 725–8.
PubMed Web of Science® Google Scholar
15 Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713–22.
10.1182/blood-2007-03-055749
CAS PubMed Web of Science® Google Scholar
16 Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase I–II trial results. J Clin Oncol 2001; 19: 2456–71.
10.1200/JCO.2001.19.9.2456
CAS PubMed Web of Science® Google Scholar
17 Querfield C, Rosen ST, Guitart J et al. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance and survival in cutaneous T-cell lymphoma. J Am Acad Dermatol 2004; 51: 25–32.
10.1016/j.jaad.2003.11.058
PubMed Web of Science® Google Scholar
18 Richardson SK, Newton SB, Bach TL et al. Bexarotene blunts malignant T-cell chemotaxis in Sézary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine. Am J Hematol 2007; 82: 792–7.
10.1002/ajh.20952
CAS PubMed Web of Science® Google Scholar
19 Gniadecki R, Assaf C, Bagot M et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br J Dermatol 2007; 157: 433–40.
10.1111/j.1365-2133.2007.07975.x
CAS PubMed Web of Science® Google Scholar
20 Bouwhis SA, Davis MDP, El-Azhary RA et al. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients. J Am Acad Dermatol 2005; 52: 991–6.
10.1016/j.jaad.2005.02.055
PubMed Web of Science® Google Scholar
21 Guitart J, Tucker R, Stevens V. Low dose bexarotene capsules and phototherapy for early stage cutaneous T-cell lymphoma. J Invest Dermatol 2002; 119: 241 [Abstr.].
Web of Science® Google Scholar
22 Gerami P, Rosen S, Kuzel T et al. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T cell lymphoma. Arch Dermatol 2008; 144: 738–46.
10.1001/archderm.144.6.738
PubMed Web of Science® Google Scholar
23 Lokitz ML, Wong HK. Bexarotene and narrowband ultraviolet B phototherapy combination treatment for mycosis fungoides. Photodermatol Photoimmunol Photomed 2007; 23: 255–7.
10.1111/j.1600-0781.2007.00315.x
CAS PubMed Web of Science® Google Scholar
24 Heald P, Christensen J, Nankin M, Girardi M. Oral bexarotene therapy combined with phototherapy in the management of cutaneous T-cell lymphoma. J Invest Dermatol 2001; 117: 536 [Abstr.]
Web of Science® Google Scholar
25 Tsirigotis P, Pappa V, Papageorgiou S et al. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome. Br J Dermatol 2007; 156: 1379–81.
10.1111/j.1365-2133.2007.07901.x
CAS PubMed Web of Science® Google Scholar
26 Richardson S, Budgin JB, Junkins-Hopkins JM et al. Low-dose bexarotene and low-dose interferon alfa-2b for adult T-cell leukaemia/lymphoma associated with human T-lymphotropic virus 1. Arch Dermatol 2005; 141: 301–4.
10.1001/archderm.141.3.301
CAS PubMed Web of Science® Google Scholar
27 French LE, Shapiro M, Junkins-Hopkins M et al. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. J Am Acad Dermatol 2001; 45: 914–18.
10.1067/mjd.2001.117519
CAS PubMed Web of Science® Google Scholar
28 Straus DJ, Duvic M, Kuzel T et al. Results of a phase II trial of oral bexarotene combined with interferon alfa-2b for patients with cutaneous T-cell lymphoma. Blood 2004; 104: 2644 [Abstr.].
Google Scholar

Citing Literature

Volume160, Issue6

June 2009

Pages 1299-1307

Bexarotene therapy for mycosis fungoides and Sézary syndrome

Summary

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Bexarotene therapy for mycosis fungoides and Sézary syndrome

Summary

References

Citing Literature

References

Related

Information